Seroatlas · Human Serome Atlas

AGT

Angiotensinogen

Also known as: ANGT_HUMAN, SERPINA8

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession
P01019
Gene
AGT
Ensembl
ENSG00000135744
Chromosome
1
Canonical length
476 aa
Protein class
Candidate cardiovascular disease genes, Disease related genes, Human disease related genes, Metabolic proteins, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins
Secretome location
Secreted to blood

OverviewNCBI Gene

The protein encoded by this gene, pre-angiotensinogen or angiotensinogen precursor, is expressed in the liver and is cleaved by the enzyme renin in response to lowered blood pressure. The resulting product, angiotensin I, is then cleaved by angiotensin converting enzyme (ACE) to generate the physiologically active enzyme angiotensin II. The protein is involved in maintaining blood pressure, body fluid and electrolyte homeostasis, and in the pathogenesis of essential hypertension and preeclampsia. Mutations in this gene are associated with susceptibility to essential hypertension, and can cause renal tubular dysgenesis, a severe disorder of renal tubular development. Defects in this gene have also been associated with non-familial structural atrial fibrillation, and inflammatory bowel disease. [provided by RefSeq, Nov 2019]

Canonical amino-acid sequenceUniProt

476 residues, UniProt reviewed canonical sequence.

>P01019|AGT
     1  MAPAGVSLRA TILCLLAWAG LAAGDRVYIH PFHLVIHNES TCEQLAKANA GKPKDPTFIP
    61  APIQAKTSPV DEKALQDQLV LVAAKLDTED KLRAAMVGML ANFLGFRIYG MHSELWGVVH
   121  GATVLSPTAV FGTLASLYLG ALDHTADRLQ AILGVPWKDK NCTSRLDAHK VLSALQAVQG
   181  LLVAQGRADS QAQLLLSTVV GVFTAPGLHL KQPFVQGLAL YTPVVLPRSL DFTELDVAAE
   241  KIDRFMQAVT GWKTGCSLMG ASVDSTLAFN TYVHFQGKMK GFSLLAEPQE FWVDNSTSVS
   301  VPMLSGMGTF QHWSDIQDNF SVTQVPFTES ACLLLIQPHY ASDLDKVEGL TFQQNSLNWM
   361  KKLSPRTIHL TMPQLVLQGS YDLQDLLAQA ELPAILHTEL NLQKLSNDRI RVGEVLNSIF
   421  FELEADEREP TESTQQLNKP EVLEVTLNRP FLFAVYDQSA TALHFLGRVA NPLSTA

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against AGT can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability
Secreted
Secreted
Yes
Transmembrane segments
0
Mean surface accessibility (rSASA)
0.26
Highest tissue expression
1,555 nTPM

Expression across tissuesHPA

Tissue

  • liver: 1,555 nTPM
  • basal ganglia: 269 nTPM
  • amygdala: 241 nTPM
  • midbrain: 207 nTPM
  • cerebral cortex: 171 nTPM
  • hippocampal formation: 161 nTPM

Single-cell type

  • hepatocytes: 2,176 nCPM
  • cholangiocytes: 1,050 nCPM
  • ependymal cells: 249 nCPM
  • astrocytes: 212 nCPM
  • epididymal efferent duct absorptive cells: 174 nCPM
  • pericytes: 78 nCPM

Immune cell

  • basophil: 0 nTPM
  • classical monocyte: 0 nTPM
  • eosinophil: 0 nTPM
  • gdT-cell: 0 nTPM
  • intermediate monocyte: 0 nTPM
  • MAIT T-cell: 0 nTPM

Brain region

  • medulla oblongata: 515 nTPM
  • spinal cord: 490 nTPM
  • white matter: 435 nTPM
  • midbrain: 433 nTPM
  • thalamus: 348 nTPM
  • cerebellum: 327 nTPM

DiseaseUniProt · ClinVar · IEDB · PubMed

Four sources answering four different questions about AGT.

Disease | AllUniProt

Conditions AGT is implicated in, by any mechanism.

Disease | GeneticClinVar

17 pathogenic / likely-pathogenic of 266 ClinVar records.

Conditions with pathogenic or likely-pathogenic variants.

Disease | AutoantibodyPubMed

Conditions in which antibodies against AGT are reported. Each links to that disease's full target list.

Showing 4 of 5 — disease pages carrying at least 10 antigens.

ReferencesPubMed · IEDB

Publications for AGT from three distinct lines of evidence, kept separate because they answer different questions: whether antibodies are directed at the protein, whether a B-cell epitope has been mapped on it, and whether a T-cell epitope has. Each is labelled with its source.

Reference: AutoantibodyPubMed

88 publications

Show 20 more of 88 total

Sources: PubMed — antigen-level antibody evidence from a custom retrieval. Records matching a controlled set of autoantibody terms (the MeSH descriptors Autoantibodies and Autoantigens, with title and abstract term variants) were obtained through NCBI E-utilities, and their titles and abstracts parsed for constructions that direct an antibody at a named protein rather than for co-occurrence. Captured names were resolved against UniProt nomenclature and each antigen adjudicated individually against the source text. Bibliographic records from PubMed and MeSH, U.S. National Library of Medicine; citation metrics from NIH iCite (Hutchins et al., PLoS Biology 2016). Titles link to PubMed; abstracts are not reproduced here. The NLM does not endorse this analysis.

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance)
1.45
gnomAD pLI
0
gnomAD missense Z
-0.2
DepMap mean gene effect
0.03
DepMap dependency class
selective

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 3% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

InteractionsUniProt · HPA

Protein binding partners of AGT in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads AGT as an antibody target. Whether an autoantibody or antibody against AGT could matter depends on whether native AGT is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

AGT is annotated as secreted, so native AGT circulates and is directly accessible to antibodies. Secreted and cell-surface proteins are the autoantibody targets most likely to act like drugs, blocking or depleting the native protein.

Annotation status

The present source text does not explicitly label AGT as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Canonical record: https://seroatlas.com/gene/AGT. Study-independent annotations aggregated from UniProt, Human Protein Atlas, PubMed, IEDB, Pfam, InterPro, Gene Ontology, AlphaFold, gnomAD, DepMap, ClinVar, TCGA. Catalog release seroatlas-reviewed-human-uniprot-20260313.

Seroatlas is the reference for exploring autoantibody and antibody serology at the human-protein level: the autoreactome and human serome, multiplex serology (HuProt, HuScan, VirScan, PhIP-Seq).

Loading the interactive Seroatlas protein explorer...